LumiThera
Jennifer DelPrete has a diverse work experience spanning over several companies and roles. Jennifer currently holds the position of Vice President of Customer Success at LumiThera, Inc. since 2022. Previously, they served as the Vice President of Customer Success at MacuLogix - The AMD Experts from 2019 to 2022. Prior to that, they held the role of Director Practice Management East at MacuLogix from 2019 to 2020. Before joining MacuLogix, they worked as Ocular Surface Application Specialists at Johnson & Johnson Vision from 2017 to 2019. Jennifer also served as the Manager of Practice Implementation at Optovue from 2011 to 2017 and as the Regional Clinical Specialist/Customer Focus Team Manager at Optos from 2002 to 2011. Jennifer began their career as a Technical Support Specialist at TLC The Laser Center from 1996 to 2002 and as an Operating Room Scrub Technician at Horizon Eye Care NJ from 1987 to 1996.
Jennifer DelPrete obtained a BS degree in Biology from Saint Joseph's University during the period of 1991 to 1995. Jennifer has also received additional certifications, including a Certified Paraoptometric CPO in February 2008 and a Certified Ophthalmic Assistant COA in November 2001.
This person is not in any teams
This person is not in any offices
LumiThera
1 followers
At LumiThera, they are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. They will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area.